[go: up one dir, main page]

MY126358A - Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs - Google Patents

Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs

Info

Publication number
MY126358A
MY126358A MYPI97001186A MYPI9701186A MY126358A MY 126358 A MY126358 A MY 126358A MY PI97001186 A MYPI97001186 A MY PI97001186A MY PI9701186 A MYPI9701186 A MY PI9701186A MY 126358 A MY126358 A MY 126358A
Authority
MY
Malaysia
Prior art keywords
tpgs
vitamin
compositions
water soluble
tocopherol derivative
Prior art date
Application number
MYPI97001186A
Inventor
Arup K Roy
Lloyd Gary Tillman
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9606372.2A external-priority patent/GB9606372D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MY126358A publication Critical patent/MY126358A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

PHARMACEUTICAL FORMULATIONS CONTAINING HIV PROTEASE INHIBITORS, SPECIFICALLY INCLUDING 3S-[3R*(1R*,2S*)]-[[(4-AMINOPHENYL ](2-METHYLPROPYL)-AMINO]-2-HYDROXY-1-PHENYLMETHYL)PROPYL]CARBAMIC ACID, TETRAHYDRO-3-FURANYL ESTER (ALTERNATIVELY KNOWN AS VX 478 OR 141W94), AND A TOCOPHERAL, AND THEIR USE IN MEDICAL THERAPY ARE DESCRIBED.
MYPI97001186A 1996-03-22 1997-03-20 Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs MY126358A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1389396P 1996-03-22 1996-03-22
GBGB9606372.2A GB9606372D0 (en) 1996-03-26 1996-03-26 Pharmaceutical formulations

Publications (1)

Publication Number Publication Date
MY126358A true MY126358A (en) 2006-09-29

Family

ID=26308992

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI97001186A MY126358A (en) 1996-03-22 1997-03-20 Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs

Country Status (12)

Country Link
JP (1) JP3117726B2 (en)
AR (1) AR006345A1 (en)
BG (1) BG64457B1 (en)
CO (1) CO4790151A1 (en)
HU (1) HU228026B1 (en)
ID (1) ID16781A (en)
IL (1) IL126185A (en)
MY (1) MY126358A (en)
OA (1) OA10880A (en)
PL (1) PL187919B1 (en)
TW (1) TW455491B (en)
WO (1) WO1997035587A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998008490A1 (en) * 1996-09-01 1998-03-05 Pharmos Corporation Solid coprecipitates for enhanced bioavailability of lipophilic substances
WO1998057648A1 (en) * 1997-06-16 1998-12-23 Vertex Pharmaceuticals Incorporated Methods of increasing the bioavailability of stable crystal polymorphs of a compound
US5891845A (en) * 1997-11-21 1999-04-06 Fuisz Technologies Ltd. Drug delivery systems utilizing liquid crystal structures
ES2140329B1 (en) * 1997-12-04 2000-10-16 Univ Granada USE OF MASLINIC ACID AS A PROTEASE INHIBITOR FOR THE TREATMENT OF DISEASE CAUSED BY THE VIRUSES OF ACQUIRED IMMUNODEFICIENCY.
GB9812189D0 (en) * 1998-06-05 1998-08-05 Glaxo Group Ltd Methods and compositions for increasing penetration of HIV protease inhibitors
WO2002051414A1 (en) * 2000-12-22 2002-07-04 Takeda Chemical Industries, Ltd. Medicinal compositions for oral use
AU2002350719A1 (en) 2002-11-29 2004-06-23 Janssen Pharmaceutica N.V. Pharmaceutical compositions comprising a basic respectively acidic drug compound, a surfactant and a physiologically tolerable water-soluble acid respectively base
US7423004B2 (en) 2003-01-31 2008-09-09 Smithkline Beecham Corporation Solid dispersion compositions
ATE533473T1 (en) * 2004-09-24 2011-12-15 Boehringer Ingelheim Pharma NEW CLASS OF SURFUCT-LIKE MATERIALS WITH VITAMIN E-TPGS AND WATER SOLUBLE POLYMER
CN101031284A (en) * 2004-09-30 2007-09-05 伊斯曼化学公司 Pharmaceutical formulations containing vitamin e tpgs molecules that solubilize lipophilic drugs without significant efflux inhibition, and use of such formulations
EP1880715A1 (en) * 2006-07-19 2008-01-23 Abbott GmbH & Co. KG Pharmaceutically acceptable solubilizing composition and pharmaceutical dosage form containing same
SA109300195B1 (en) * 2008-03-28 2013-04-20 Astrazeneca Ab A Novel Anti-Cancer Pharmaceutical Composition
ITRM20120331A1 (en) 2012-07-12 2014-01-13 Guidotti & C Spa Labor LIQUID ORAL PEDIATRIC COMPOSITIONS CONTAINING NEPADUTANT.

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1677092A (en) * 1991-03-20 1992-10-21 Vertex Pharmaceuticals Incorporated Tetrahydroxyalkane derivatives as inhibitors of hiv aspartyl protease
ATE163926T1 (en) * 1991-11-08 1998-03-15 Merck & Co Inc HIV PROTEASE INHIBITORS USABLE IN AIDS TREATMENT
IS2334B (en) * 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl protease inhibitor of a new class of sulfonamides
AU5748194A (en) * 1992-12-11 1994-07-04 Vertex Pharmaceuticals Incorporated Mannitol derivatives and their use as inhibitors of aspartyl protease
US5484926A (en) * 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
EP0674513B1 (en) * 1992-12-29 1996-09-25 Abbott Laboratories Retroviral protease inhibiting compounds
CA2153777A1 (en) * 1993-01-15 1994-07-21 Siegfried H. Reich Hiv protease inhibitors
WO1995012583A1 (en) * 1993-11-05 1995-05-11 Merck & Co., Inc. New quinazolines as inhibitors of hiv reverse transcriptase
IL111584A0 (en) * 1993-11-18 1995-01-24 Merck & Co Inc Prodrugs of an inhibitor of hiv protease and pharmaceutical compositions containing them
PL314984A1 (en) * 1993-12-15 1996-09-30 Merck & Co Inc Hiv protease inhibitors
CA2183653A1 (en) * 1994-03-07 1995-09-14 Roger Dennis Tung Sulphonamide derivatives as aspartyl protease inhibitors
GB9409778D0 (en) * 1994-05-16 1994-07-06 Dumex Ltd As Compositions
US5527829A (en) * 1994-05-23 1996-06-18 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
WO1996036316A1 (en) * 1995-05-19 1996-11-21 Abbott Laboratories Self-emulsifying formulations of lipophilic drugs

Also Published As

Publication number Publication date
JP3117726B2 (en) 2000-12-18
OA10880A (en) 2001-10-11
BG64457B1 (en) 2005-03-31
TW455491B (en) 2001-09-21
HUP9901887A2 (en) 1999-12-28
PL328916A1 (en) 1999-03-01
HU228026B1 (en) 2012-08-28
IL126185A0 (en) 1999-05-09
BG102838A (en) 1999-09-30
HUP9901887A3 (en) 2000-02-28
PL187919B1 (en) 2004-11-30
AR006345A1 (en) 1999-08-25
CO4790151A1 (en) 1999-05-31
WO1997035587A1 (en) 1997-10-02
ID16781A (en) 1997-11-13
IL126185A (en) 2003-05-29
JP2000500504A (en) 2000-01-18

Similar Documents

Publication Publication Date Title
MY126358A (en) Compositions comprising vx478 and a water soluble tocopherol derivative such as vitamin e-tpgs
AU6628496A (en) Polyether block copolymer micellar compositions for targeting biological agents
PT762896E (en) TOCOFEROL COMPOSITIONS FOR THE ADMINISTRATION OF BIOLOGICALLY ACTIVE AGENTS
ECSP034883A (en) AMIDAS OF ANTRANILIC ACIDS WITH SIDE CHAIN OF HETEROARILSULFONILO, PROCEDURE FOR THEIR PREPARATION, ITS EMPLOYMENT AS A MEDICINAL OR DIAGNOSTIC AGENT, AS WELL AS PHARMACEUTICAL PREPARATIONS CONTAINING THEM
ATE533472T1 (en) LIQUID CANNABINOID FORMULATIONS FOR ADMINISTRATION TO THE MUCOUS MEASURES
ES2233931T3 (en) PHENYLACETATE AND DERIVATIVES, ALONE OR IN COMBINATION WITH OTHER COMPOUNDS, AGAINST NEOPLASIC STATES AND OTHER DISORDERS.
IL114193A0 (en) Ophthalmic pharmaceutical compositions
PA8575701A1 (en) ACID INSULIN PREPARATIONS WITH IMPROVED STABILITY
MXPA05002814A (en) Formulation for lipophilic agents.
ES2156028T3 (en) Compositions containing tetrahydrolipstatin
TR200001977T2 (en) Compositions containing lipophilic glucocorticosteroid micelles
WO2001038303A3 (en) Vitamin d analogues
HUP0100539A2 (en) Pharmaceutical compositions containing vitamin d and calcium, their preparation and therapeutic use
BR0304298A (en) Composition containing a cosmetically active organic acid and a vegetable product
RU95106680A (en) Bicyclic aromatic compounds and pharmaceutical and cosmetic compositions comprising them
HUP0004375A2 (en) Composition containing azelaic acid
HUP0304077A2 (en) Pharmaceutical and cosmetic compositions against skin aging
UA10208A (en) Dermatological cosmetic preparation
MXPA03010628A (en) Vitamin d analogues.
PA8449301A1 (en) PHARMACEUTICAL COMPOSITIONS
CO4970832A1 (en) NEW FORMULATIONS AND PROCESSES FOR ITS MANUFACTURE
ATE201137T1 (en) SEMI-SOLID PHARMACEUTICAL PREPARATIONS CONTAINING DEXKETOPROFEN-TROMETAMOLE
EP1429723A4 (en) Treating effects of excessive reactive oxygen species
AU3739500A (en) Protease resistant flint analogs
CA2249336A1 (en) Compositions comprising an hiv protease inhibitor such as vx 478 and a water soluble vitamin e compound such as vitamin e-tpgs